Suppliers

China okays emergency use of CanSinoBio’s Convidecia Air inhaled COVID-19 vaccine

According to CanSino Biologics, China’s National Medical Products Administration (NMPA) has approved the company’s Convidecia Air nebulized COVID-19 vaccine as a booster dose. In December 2021, CanSino Bio announced a deal with Aerogen for the use of Aerogen vibrating mesh nebulizers for delivery of the adenovirus vector vaccine.

?We are pleased to announce #Convidecia Air receives approval in China today. This marks the first approval of the inhaled version of COVID-19 vaccine globally! It is needle-free and can effectively induce comprehensive immune protection after just one breath.
— CanSino Biologics Inc. (@cansinobio_inc) September 4, 2022

Chinese vaccine manufacturer CanSino’s inhaled COVID-19 vaccine has been included in the national emergency use list as a booster, the firm said on Sunday. pic.twitter.com/Z6XkYYQ2LI
— Global Times (@globaltimesnews) September 4, 2022

published on

September 9, 2022

Featured event:

Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

July 28: Webinar: Inhaled Dissolution: Principles, Challenges and Applications, online

September 15-September 18: DDL New Researcher Network Summer Event, London, UK

September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA

September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK

October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA

See all upcoming events

Suppliers